噻唑烷二酮类药物对骨骼的影响  

Effects of thiazolidinedione on the bone

作　　者：陈胜广[1] 吴国亭[1] 

机构地区：[1]上海市第十人民医院内分泌科,上海200072

出　　处：《国际内分泌代谢杂志》2009年第B04期16-18,共3页International Journal of Endocrinology and Metabolism

摘　　要：短期临床试验证实，女性骨量丢失与应用噻唑皖二酮类药物（TZDs）有关。TZDs广泛应用于糖尿病治疗，因此了解其对骨骼作用对临床实践非常重要。有研究表明，罗格列酮能导致骨丢失。糖尿病转归和进展试验（ADOPT）中也出现了骨折率的差异，这种差异可能由TZDs导致的骨量减少引起。动物实验和体外细胞培养显示过氧化物酶体增殖物活化受体γ促进脂肪形成，抑制成骨细胞分化，降低骨形成，减少骨量。In women,short-term clinical trials demonstrated substantial bone loss with thiazolidinedi- one. Pioglitazone and rosiglitazone are widely used to treat diabetes, and better knowledge of their skeletal effects is crucial to guide clinical decisions. The randomized trial provides that rosiglitazone causes bone loss. An imbalance in fracture rates was identified in a final review of adverse event reports in ADOPT trial. That may result from the loss of bone mass due to thiazolidinedione. Animal and in vitro studies suggest that activtion of PPARγ, promotes adipogenesis at the expense of osteoblastogenesis, and therefore inhibit bone formation and induce bone loss.

关 键 词：噻唑烷二酮类药物 过氧化物酶体增殖物活化受体Γ 骨质疏松 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌] R544.1[医药卫生—内科学]